XML 24 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
PHARMACEUTICAL DEVELOPMENT PROJECT (Details Narrative) - USD ($)
6 Months Ended
Dec. 28, 2021
Jun. 30, 2022
Restructuring Cost and Reserve [Line Items]    
Research and Development in Process   $ 2,186,917
Fair Value, Inputs, Level 2 [Member]    
Restructuring Cost and Reserve [Line Items]    
Assets, Fair Value Disclosure   $ 2,186,917
Sapir Pharmaceuticals Inc [Member] | Series A Preferred Stock [Member]    
Restructuring Cost and Reserve [Line Items]    
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares 1,000,000